| Sygnia Itrix Health Innovation AMETF
Type: Active ETF |
JSE code: SYGH |
| Benchmark: Solactive Developed Markets Healthcare 150 | Classification: Global Equity |
| Tax-free investing: Allowed (What is tax-free?) | Market cap: R 195 Million |
| TIC (TER where TIC not indicated): 0.55000000000000004% (What is TER?) | Distribution: Semi Annual | Jul-25: 16.87887, Jan-26: 10.30382 (cents/unit) |
| Returns as per MDD and annualised to the date of the MDD publication.
1 year 7.9% | 3 year 1.2% | 5 year % | Since listing 5.7% |
|
| Top holdings:
Eli Lilly Ord Shs (11.2%), Johnson & Johnson Ord Shs (6.8%), AbbVie Ord Shs (4.9%), UnitedHealth Group Ord Shs (4.2%), Merck & Co Ord Shs (3.5%), Roche PS Par Shs (3.2%), Novartis Ord Shs (3.1%), Astrazeneca Ord Shs (3.1%), Amgen Ord Shs (2.2%), Thermo Fisher Scientific Ord Shs (2.1%) |
|
| MDD updated: 30 June 2026 (Understanding your MDD)
MDD web link here (BETA): |
|
| Description:
The fund aims to provide investors access to healthcare innovation stocks and deliver long-term capital growth |
|
All data from the issuer Minimum Disclosure Documents (MDD) and updated as they update their MDDs. Please check all data, we take no responsibility for errors.